Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hexatronic in conjunction with an acquisition in the United States
Mandate

Vinge advises Hexatronic in conjunction with an acquisition in the United States

December 12, 2017

Vinge, together with Ellis & Winter LLP, has advised Hexatronic Group AB (publ) in connection with the acquisition of Blue Diamond LLC (BDI), Lexington, Kentucky.


BDI manufactures High Density Polyethylene (HDPE) conduits and pipes for the telecommunications and utilities industries.

BDI has a turnover of approximately MUSD 29 with an EBITDA of approximately MUSD 4 and has 85 employees. The purchase price on a debt-free basis amounts to MUSD 24.5 with a maximum supplementary purchase price of MUSD 2.5.

Vinge’s team was led by Anders Strid.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026